Health · 1 sources covering this

STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a reverse-merger with a preexisting biotech company.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal
A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a reverse-merger with a preexisting biotech company.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/b8c755058d1054e2284c3063906e10c00e531dbd"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal"></iframe>

STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

How 1 sources are covering this

STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

More from Health

STAT+: Pharmalittle: We’re reading about FDA reforming clinical trials, a Pfizer setback, and much more news

STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

STAT+: OpenEvidence will add FDA-cleared AI to detect heart disease

HHS has sent drug for Ebola clinical trial

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

More from Health

STAT+: Pharmalittle: We&#8217;re reading about FDA reforming clinical trials, a Pfizer setback, and much more news

STAT+: Lilly&#8217;s retatrutide has been offered to a single person via &#8216;compassionate use&#8217; program

STAT+: OpenEvidence will add FDA-cleared AI to detect heart disease

HHS has sent drug for Ebola clinical trial

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about FDA reforming clinical trials, a Pfizer setback, and much more news

STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program